NCT02038907View on ClinicalTrials.gov

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

March 28, 2014

Primary Completion Date

June 19, 2015

Study Completion Date

June 19, 2015

Conditions
Healthy VolunteersNorovirus, Prevention
Interventions
BIOLOGICAL

Hepatitis A Vaccine

Hepatitis A Vaccine IM injection

BIOLOGICAL

Norovirus Bivalent VLP Vaccine

Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection

Trial Locations (2)

2650

Universiteit Antwerpen, Edegem

9000

Universitair Ziekenhuis Gent, Ghent

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY